Previous close | 9.51 |
Open | 9.50 |
Bid | 9.39 x 1800 |
Ask | 9.44 x 2600 |
Day's range | 9.17 - 9.58 |
52-week range | 4.97 - 16.75 |
Volume | |
Avg. volume | 6,234,654 |
Market cap | 2.239B |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 14, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), executed a sale of 20,054 shares of the company.
Recursion Pharmaceuticals ( NASDAQ:RXRX ) First Quarter 2024 Results Key Financial Results Revenue: US$13.8m (up 14...
Insight into Recursion Pharmaceuticals' Financial Health and Strategic Advances